Skip to content
MarketScale
‹ Back to Industries

Sciences

NASA Joins the International Effort to Learn More About Norway’s Auroral Cusp

A solar wind of ionized particles from the sun is constantly blowing through the solar system. Earth’s only protection from this wind is its magnetic field, which emerges from the north pole, wraps around the earth, and re-enters the earth at the south pole. Mars has no atmosphere because, after it lost its protective magnetic…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences ·
Share

Key takeaways

01

A solar wind of ionized particles from the sun is constantly blowing through the solar system.

02

Earth’s only protection from this wind is its magnetic field, which emerges from the north pole, wraps around the earth, and re-enters the earth at the south pole.

03

Mars has no atmosphere because, after it lost its protective magnetic…

A solar wind of ionized particles from the sun is constantly blowing through the solar system. Earth’s only protection from this wind is its magnetic field, which emerges from the north pole, wraps around the earth, and re-enters the earth at the south pole. Mars has no atmosphere because, after it lost its protective magnetic field, the solar winds literally blew the atmosphere away. The earth’s active magnetic field is what keeps the same thing from happening here, and life disappearing from earth.

Near the poles, however, where the magnetic field bends in toward the earth, the solar wind can come into contact with the atmosphere, heating up the atmosphere and causing the auroras as the ionized particles bombard air molecules. According to Eureka Alert!, “North of Norway over the Norwegian and Greenland Seas, the magnetic bubble surrounding the Earth dips inward, allowing space particles to funnel in toward the planet.” This cusp, where energy from the solar wind “heats the atmosphere by hundreds of degrees,” is actually visible to the naked eye in November and December.

This is why “eight missions with 11 rockets will launch from two sites in Norway—Andøya Space Center and Svalbard Rocket Range” around this time in 2018 and 2019. “The first mission—a NASA mission called the Auroral Zone Upwelling Rocket Experiment, or AZURE—launches in March 2018.” NASA will also launch “the Visualizing Ion Outflow via Neutral Atom Sensing-2 experiment or VISIONS-2” in December 2018. There will also be the “Norwegian Investigation of Cusp Irregularities-5 or ICI-5 mission in December 2019.”

The Eureka Alert website further explains, “In addition to AZURE, VISIONS-2 and ICI-5, other NASA Grand Challenge missions are the Twin Rockets to Investigate Cusp Electrodynamics or TRICE-2 (led by the University of Iowa, launching December 2018), The Cusp Alfven and Plasma Electrodynamics Rocket or CAPER-2 (led by Dartmouth University, launching January 2019), and the Cusp-Region Experiment or C-REX 2 (led by the University of Alaska, launching November 2019), which also includes three Canadian instruments from the University of Calgary (also flying on VISIONS-2).” Furthermore, “The Japan Aerospace Exploration Agency (JAXA) will fly the SS-520-3 in January 2019, which investigates the ion outflow mechanism in the cusp.”

The next year will be exciting for both atmospheric and space science at the international level. By learning more about this unique feature in our atmosphere created by the earth’s magnetic field, we will learn more about the solar wind, how the solar wind interacts with the atmosphere, and how our magnetic field protects life on earth. So, stay tuned to science news over the next several years as new data surfaces and more knowledge about the cusp is created.

About the author

S
Sciences

New to MarketScale?

MarketScale is the platform Sciences companies use to turn their own experts into content like this. Want the short overview?

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Tekniplex Showcases Sustainable Materials Innovation at Paris Packaging Week 2026

Tekniplex Showcases Sustainable Materials Innovation at Paris Packaging Week 2026

At Paris Packaging Week 2026, Tekniplex showcased its latest sustainable materials innovations, emphasizing the intersection of materials science and brand storytelling. The company's booth featured a living wall and digital displays to engage a sustainability-conscious audience, highlighting advanced materials for sustainability and product performance in cosmetics packaging.

  • 01Tekniplex emphasized sustainable materials innovation at Paris Packaging Week 2026.
  • 02The company's booth featured eco-friendly design elements and immersive digital displays.
  • 03Tekniplex highlighted advancements in recyclable sealing systems and materials for cosmetics.

Apr 9, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences